Lebrikizumab-lbkz injection is a sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous use. Lebrikizumab-lbkz is available as either a 250 mg/2 mL single-dose prefilled pen or a single-dose prefilled syringe with needle shield. The lebrikizumab-lbkz prefilled pen and prefilled syringe with needle shield are not made with natural rubber latex.1

Each prefilled pen or prefilled syringe delivers 250 mg lebrikizumab-lbkz in 2 mL solution which also contains glacial acetic acid (1.8 mg), histidine (6.2 mg), polysorbate 20 (0.6 mg), sucrose (119.6 mg) and Water for Injection. The pH is 5.4 – 6.0.1

The recommended dosage of lebrikizumab-lbkz is an initial dose of 500 mg (two 250 mg injections) at week 0 and week 2, followed by 250 mg (one injection) every 2 weeks until week 16 or later, when adequate clinical response is achieved. The maintenance dose is 250 mg every 4 weeks.1

Lebrikizumab-lbkz can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas.1

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.1

There is no specific treatment for lebrikizumab-lbkz overdose. Single intravenous doses up to 10 mg/kg and multiple subcutaneous doses up to 500 mg have been administered to humans in clinical trials without dose-limiting toxicity.2 In the event of overdosage, contact Poison Control (1-800-222-1222) for the latest recommendations. Monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.1